NTLA
Intellia Therapeutics, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth -30.0% ·
share flow -2.5% ·
net new positions -20.0%
· formula
Broad distribution: falling shares and fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q1 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 4 | +1 | 344.31K | $4.16M | +1 | n/a |
| Q2 2026 | 108 | +3 | 103.12M | $1.74B | +8 | −5 |
| Q1 2026 | 108 | +4 | 82.71M | $1.06B | +13 | −9 |
| Q4 2025 | 104 | -1 | 82.78M | $744.21M | +1 | −2 |
| Q3 2025 | 18 | +2 | 59.30M | $1.02B | +2 | −1 |
| Q2 2025 | 14 | +2 | 47.63M | $446.74M | +2 | n/a |
| Q1 2025 | 9 | -4 | 25.51M | $181.35M | n/a | −4 |
| Q4 2024 | 13 | +3 | 26.17M | $305.16M | +3 | n/a |
| Q3 2024 | 9 | 0 | 18.08M | $371.64M | +1 | −1 |
| Q2 2024 | 9 | n/a | 17.86M | $399.79M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | ARK Investment Management ✦ | 13.01M | +3.8% | $92.51M | 0.9% | ▲ Add | 4 | SEC ↗ |
| 2 | State Street Global Advisors ✦ (passive) | 4.51M | -13.4% | $32.07M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 3 | Citadel Advisors ✦ | 2.76M | +10.6% | $19.61M | 0.0% | ▲ Add | 4 | SEC ↗ ×2 |
| 4 | Geode Capital Management ✦ (passive) | 2.48M | +3.8% | $17.64M | 0.0% | ▲ Add | 4 | SEC ↗ ×2 |
| 5 | Two Sigma Investments ✦ | 1.99M | +8.1% | $14.17M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 6 | Millennium Management ✦ | 586.49K | -12.3% | $4.17M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 7 | AQR Capital Management ✦ | 90.88K | +154.2% | $646,122 | 0.0% | ▲ Add | 2 | SEC ↗ ×5 |
| 8 | T. Rowe Price ✦ | 43.91K | +11.7% | $313,000 | 0.0% | ▲ Add | 4 | SEC ↗ |
| 9 | D. E. Shaw & Co. ✦ | 32.40K | -3.5% | $230,336 | 0.0% | ▼ Trim | 3 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| Wellington Management | $8.16M | was 0.0% |
| Renaissance Technologies | $1.15M | was 0.0% |
| Marshall Wace | $1.11M | was 0.0% |
| Norges Bank | $349,917 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 1 holders, 22.80K shares, $292 reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 1.86K sh · $23,170
Officer, Director · 2.79K sh · $36,205
Officer, Director · 19.89K sh · $250,614
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology